- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 3/00 - Drugs for disorders of the metabolism
Patent holdings for IPC class A61P 3/00
Total number of patents in this class: 6714
10-year publication summary
|
291
|
257
|
242
|
388
|
466
|
468
|
556
|
503
|
496
|
148
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Mondobiotech Laboratories AG | 311 |
282 |
| F. Hoffmann-La Roche AG | 7958 |
73 |
| Janssen Pharmaceutica N.V. | 3839 |
67 |
| Takeda Pharmaceutical Company Limited | 2961 |
64 |
| Bristol-myers Squibb Company | 5080 |
61 |
| Boehringer Ingelheim International GmbH | 4629 |
58 |
| Novartis AG | 11238 |
50 |
| Amicus Therapeutics, Inc. | 341 |
42 |
| Pfizer Inc. | 3322 |
39 |
| Eli Lilly and Company | 3645 |
37 |
| Regeneron Pharmaceuticals, Inc. | 3650 |
37 |
| Modernatx, Inc. | 1181 |
35 |
| sanofi-aventis | 427 |
33 |
| Amgen Inc. | 3779 |
32 |
| University of Pittsburgh - Of the Commonwealth System of Higher Education | 2912 |
32 |
| Société des Produits Nestlé S.A. | 9672 |
30 |
| The Regents of the University of California | 18943 |
30 |
| Merck Patent GmbH | 5909 |
30 |
| Genzyme Corporation | 1205 |
29 |
| AstraZeneca AB | 3042 |
28 |
| Other owners | 5625 |